Page 70 - AN-3-2

Advanced Neurology Inflammation in diabetic stroke: Treatment target

Funding (EDIC) Study Research Group. Intensive diabetes treatment
and cardiovascular outcomes in type 1 diabetes: The
None. DCCT/EDIC study 30-year follow-up. Diabetes Care.
2016;39(5):686-693.
Conflict of interest
doi: 10.2337/dc15-1990
The authors declare that they have no conflicts of interest.
7. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M,
Author contributions et al. Effect of intensive glucose lowering treatment on all
cause mortality, cardiovascular death, and microvascular
Conceptualization: Liqun Zhang, Yun Xu events in type 2 diabetes: Meta-analysis of randomised
Writing – original draft: Liqun Zhang, Ying Chen, Jingxian controlled trials. BMJ. 2011;343:d4169.
Xu doi: 10.1136/bmj.d4169
Writing – review & editing: All authors
8. Muller TD, Finan B, Bloom SR, et al. Glucagon-like peptide
Ethics approval and consent to participate 1 (GLP-1). Mol Metab. 2019;30:72-130.
doi: 10.1016/j.molmet.2019.09.010
Not applicable.
9. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular,
Consent for publication mortality, and kidney outcomes with GLP-1 receptor
agonists in patients with type 2 diabetes: A systematic review
Not applicable. and meta-analysis of randomised trials. Lancet Diabetes
Endocrinol. 2021;9(10):653-662.
Availability of data
doi: 10.1016/S2213-8587(21)00203-5
Not applicable.
10. Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor
References agonists and cardiorenal outcomes in type 2 diabetes: An
updated meta-analysis of eight CVOTs. Cardiovasc Diabetol.
1. GBD 2016 Lifetime Risk of Stroke Collaborators, Feigin VL, 2021;20(1):189.
Nguyen G, et al. Global, regional, and country-specific doi: 10.1186/s12933-021-01366-8
lifetime risks of stroke, 1990 and 2016. N Engl J Med.
2018;379(25):2429-2437. 11. Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F,
Trapp S. Distribution and characterisation of Glucagon-like
doi: 10.1056/NEJMoa1804492
peptide-1 receptor expressing cells in the mouse brain. Mol
2. Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of stroke Metab. 2015;4(10):718-731.
in people with type 2 diabetes in the UK: A study using doi: 10.1016/j.molmet.2015.07.008
the General Practice Research Database. Diabetologia.
2006;49(12):2859-2865. 12. Hunter K, Holscher C. Drugs developed to treat diabetes,
liraglutide and lixisenatide, cross the blood brain barrier
doi: 10.1007/s00125-006-0493-z and enhance neurogenesis. BMC Neurosci. 2012;13:33.
3. Lee J, Yun JS, Ko SH. Advanced glycation end products and doi: 10.1186/1471-2202-13-33
their effect on vascular complications in type 2 diabetes
mellitus. Nutrients. 2022;14(15):3086. 13. Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like
peptide-1 (GLP-1) receptor agonists and neuroinflammation:
doi: 10.3390/nu14153086 Implications for neurodegenerative disease treatment.
4. Chawla D, Bansal S, Banerjee BD, Madhu SV, Kalra OP, Pharmacol Res. 2022;186:106550.
Tripathi AK. Role of advanced glycation end product doi: 10.1016/j.phrs.2022.106550
(AGE)-induced receptor (RAGE) expression in diabetic
vascular complications. Microvasc Res. 2014;95:1-6. 14. Rizzo M, Chandalia M, Patti AM, et al. Liraglutide decreases
carotid intima-media thickness in patients with type 2
doi: 10.1016/j.mvr.2014.06.010 diabetes: 8-month prospective pilot study. Cardiovasc
5. Koska J, Saremi A, Howell S, et al. Advanced glycation end Diabetol. 2014;13:49.
products, oxidation products, and incident cardiovascular doi: 10.1186/1475-2840-13-49
events in patients with type 2 diabetes. Diabetes Care.
2018;41(3):570-576. 15. Kapoor I, Sarvepalli SM, D’Alessio D, Grewal DS,
Hadziahmetovic M. GLP-1 receptor agonists and diabetic
doi: 10.2337/dc17-1740 retinopathy: A meta-analysis of randomized clinical trials.
Surv Ophthalmol. 2023;68(6):1071-1083.
6. Diabetes Control and Complications Trial (DCCT)/
Epidemiology of Diabetes Interventions and Complications doi: 10.1016/j.survophthal.2023.07.002

Volume 3 Issue 2 (2024) 9 doi: 10.36922/an.1694